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Abstract
Objective
To assess the impact of APOE polymorphisms on cognitive performance in patients newly
diagnosed with clinically isolated syndrome (CIS) or relapsing-remitting MS (RRMS).
Methods
This multicenter cohort study included 552 untreated patients recently diagnosed with CIS or
RRMS according to the 2005 revised McDonald criteria. The single nucleotide polymorphisms
rs429358 (e4) and rs7412 (e2) of the APOE haplotype were assessed by allelic discrimination
assays. Cognitive performance was evaluated using the 3-second paced auditory serial addition
test and the Multiple Sclerosis Inventory Cognition (MUSIC). Sum scores were calculated to
approximate the overall cognitive performance and memory-centered cognitive functions. The
impact of the APOE carrier status on cognitive performance was assessed using multiple linear
regression models, also including demographic, clinical, MRI, and lifestyle factors.
Results
APOE e4 homozygosity was associated with lower overall cognitive performance, whereas no
relevant association was observed for APOE e4 heterozygosity or APOE e2 carrier status.
Furthermore, higher disability levels, MRI lesion load, and depressive symptoms were asso-
ciated with lower cognitive performance. Patients consuming alcohol had higher test scores
than patients not consuming alcohol. Female sex, lower disability, and alcohol consumption
were associated with better performance in the memory-centered subtests of MUSIC, whereas
no relevant association was observed for APOE carrier status.
Conclusion
Along with parameters of a higher disease burden, APOE e4 homozygosity was identified as
a potential predictor of cognitive performance in this large cohort of patients with CIS and early
RRMS.
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MS is a chronic neuroinflammatory disease, which mostly
affects young adults. Apart from physical impairment, decline
of cognitive functions is one of its most disabling aspects. A
meta-analysis of data acquired by genome-wide association
studies identified a total of 234 significant associations and
a further 416 variants potentially associated with MS.1
However, so far, little is known about the contribution of
genetic risk factors to the development of cognitive impair-
ment in MS.
TheAPOE gene locus has been discussed as a possible mediator
of cognitive impairment as it is associated with the evolution of
dementias like Alzheimer disease (AD).2 It may encode 3 dif-
ferent isoforms of apolipoprotein E (APOE2, APOE3, and
APOE4), which are defined by the haplotype combination of
common single nucleotide polymorphisms (SNPs) at 2 nearby
loci on the APOE gene. The SNPs are labeled rs429358 (base
exchange from cytosine to thymine [C>T] leading to the
haplotype APOE e4) and rs7412 (base exchange C>T resulting
in the haplotypeAPOE e2). TheAPOE e4 haplotype leads to an
amino acid exchange from cysteine to arginine at position 112 of
the APOE protein resulting in the isoform APOE4, whereas the
haplotype APOE e2 leads to an amino acid exchange from
arginine to cysteine at position 158 of the APOE protein
resulting in the isoform APOE2. APOE e3 is the common
variant.3 APOE e4 is associated with faster memory decline over
the adult life course4 and is a major risk factor for AD, with an 8-
to 12-fold increase in APOE e4 homozygotes.3 Although it was
shown in a sufficiently powered study that APOE variants have
no effect on MS susceptibility,5 reports on the influence of
APOE variants on cognitive performance in patients with MS
have been contradictory.6,7 Therefore, this study aims to assess
the potential impact of APOE polymorphisms on parameters of
cognitive function in a large multicenter, prospectively collected
German data set of untreated patients with clinically isolated
syndrome (CIS) and early relapsing-remitting MS (RRMS). As
a number of demographic, clinical, MRI, and lifestyle risk factors
have been shown to enhance cognitive decline in MS and to
adversely influence disease progression,8–10 these were also in-
cluded in the analyses.
Methods
Standard protocol approvals, registrations,
and patient consents
This multicenter prospective longitudinal observational cohort
study (German National MS Cohort) was approved by the
ethics committee of Ruhr-University Bochum (registration no.
3714-10) and consecutively all local committees of the par-
ticipating centers (22 centers in Germany). All patients pro-
vided written informed consent.
The German National MS cohort and
clinical data
A total of 552 participants from the German National MS
cohort, a multicenter, prospective, and observational study,
were included. This study was approved by the ethics
committee of Ruhr-University Bochum (registration no.
3714-10) as described previously.11 All participants were
aged at least 18 years, untreated regarding disease-modifying
therapies, and diagnosed with either CIS with first symptoms
within the previous 6 months and fulfilling at least 3 Barkhof
criteria12 or RRMS according to the 2005 revised McDonald
criteria13 with first symptoms not more than 3 years before
study enrollment. For inclusion, patients must not have re-
ceived a steroid pulse due to a relapse in the 4 weeks before
study enrollment. All participants provided written informed
consent.
Assessments included clinical, demographic, MRI, and life-
style variables and screening tests for cognitive function and
blood sampling.11 At the point of study enrollment, patients
were asked to assess their current drinking and smoking habits
via questionnaire. In response to the question “Do you cur-
rently drink alcohol?”, patients could select from 3 categories:
(0) no, (1) occasionally, and (2) regularly. Based on this, we
dichotomized the participants into current no alcohol con-
sumers (category 0) and current alcohol consumers (cate-
gories 1 and 2). Similarly, in response to the question “Do you
currently smoke?”, patients could select from 6 categories: (0)
no, (1) occasionally, but not on a daily basis, (2) up to 5
cigarettes daily, (3) 6–10 cigarettes daily, (4) 11–20 cigarettes
daily, and (5) >20 cigarettes daily. We dichotomized the
participants into current nonsmokers (category 0) and cur-
rent smokers (all other categories). Body weight and height
were physically measured on site at the time of study enroll-
ment. Body mass index (BMI) was then calculated as BMI =
weight (kg)/height (m)2. School-level education was cate-
gorized according to the highest school leaving qualification
(level 1: lower-level secondary school [German Haupt-
schule]; level 2: higher-level secondary school; level 3: higher
education entrance qualification [German Abitur]). De-
pressive symptoms were assessed by the 21-item Beck De-
pression Inventory II (BDI-II),14 and severity of fatigue was
evaluated by the Fatigue Scale for Motor and Cognitive
Functions (FSMC).15
Glossary
AD = Alzheimer disease; BDI-II = Beck Depression Inventory II; BMI = body mass index; CIS = clinically isolated syndrome;
EDSS = Expanded Disability Status Scale; FSMC = Fatigue Scale for Motor and Cognitive Function;HWE = Hardy-Weinberg
equilibrium;MCI =mild cognitive impairment;MUSIC =Multiple Sclerosis Inventory Cognition; PASAT 3 = 3-second paced
auditory serial addition test; RRMS = relapsing-remitting MS; SNP = single nucleotide polymorphism.
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Cognitive assessment
Cognitive assessment included the 3-second paced audi-
tory serial addition test (PASAT 3) and the Multiple
Sclerosis Inventory Cognition (MUSIC) cognitive
screening tests.
The PASAT 3 is a measure of cognitive function that
assesses auditory information processing speed, working
memory, divided attention, and calculation ability. PASAT
3 data were extracted from the Multiple Sclerosis Func-
tional Composite.16 Individual PASAT 3 test scores were
z-standardized, stratified for age and education based on
normative data from a German sample of n = 241 healthy
controls.17,18
MUSIC is a brief multiple-domain cognitive screening test,
which is widely used in German-speaking countries and was
developed for the rapid assessment of the most frequently
impaired cognitive domains in patients with MS. It consists of
5 cognitive subtests. In the subtests (1) and (2), the patient is
asked to remember as many words as possible out of 2 con-
secutive word lists, each consisting of 10 different words to
evaluate working memory. In subtest (3), the patient is given
2 alternating word categories, for which they are asked to find
as many associated terms as possible within 1 minute. This
subtest was designed to test verbal fluency. Subtest (4) is
a modified Stroop Task and assesses susceptibility to in-
terference. In subtest (5), the patient is asked to recall the
terms of the first given list of words to asses memory con-
solidation.19 Individual test scores were z-standardized based
on normative data from n = 158 German-speaking healthy
young adults.17,19 All tests were taken for the first time at
study enrollment so that results were not expected to be
biased by learning effects.
Biosamples and genotyping
The SNPs rs429358 (e4) and rs7412 (e2) in APOE and the Y
chromosome marker rs2032598 (for sampling and handling
control) were analyzed using allelic discrimination assays
based on TaqMan chemistry according to the manufacturer’s
protocol (Applied Biosystems, Inc.). Genotyping was per-
formed on 96-well plates with approximately 5% controls run
in duplicates across plates. Genotyping efficiency was ≥99.6%
for all SNPs. Deviation of the genotypes from Hardy-
Weinberg equilibrium (HWE) as a potential marker for
genotyping quality was assessed using the Pearson χ2 test. The
genotype distribution of rs429358 and rs7412 did not deviate
from HWE.
MRI analysis
MRI scans of all patients with CIS and MS included
a T1-weighted sequence, a fluid-attenuated inversion re-
covery sequence, and contrast-enhanced T1-weighted
images and were analyzed by a neuroradiologist with
regard to lesion number, size, and location and to contrast-
enhancing lesions. The neuroradiologist was blinded to
clinical data.
Statistical analysis
Statistical analyses were performed using SPSS 23.0 software
(IBM Corp.). Continuous variables are described by their
median and interquartile range, and categorical variables by
numbers and percentages.
A variety of general sociodemographic factors known to in-
fluence cognitive status and previously discussed disease-
specific risk factors for cognitive impairment in MS20 were
assessed. The list of the potential predictors and their baseline
characteristics are summarized in table 1. Age and education
were not included in the further analyses as cognitive test
results had already been corrected for age and education by z-
standardization.
To approximate the overall cognitive performance of each
patient, we calculated an unweighted mean z-score:
Mean z-score = (z-score of PASAT 3 + z-score of MUSIC
total test score)/2.
In addition, the results of the memory-centered MUSIC
subtests 1, 2, and 5 were added up to form amemory-centered
sum score:
Memory-centered sum score = (z-score of verbal learning list
A + z-score of verbal learning list B + z-score of verbal re-
call)/3.
To extract those factors, which contributed most to cognitive
performance in our cohort, variables were preselected by
performing univariate linear regression analyses of each po-
tential predictor with the cognitive outcome parameter under
investigation. Variables with p values of regression coefficients
<0.1 were subsequently selected for inclusion to a multiple
linear regression model for the respective outcome. Di-
chotomous variables were dummy coded.
All our analyses are exploratory. Hence, p values are only
given for descriptive reasons. However, we consider an as-
sociation as statistically relevant in case of p < 0.05.
Data availability
The raw data used in preparation of the figures and tables will
be shared in anonymized format on request of a qualified
investigator to the corresponding author for purposes of
replicating procedures and results.
Results
Characteristics of the 552 patients included in this study are
reported in table 1. Of note, 25.2% of the patients were car-
riers of the APOE e4 allele. Ten of these (1.8%) were
homozygotes, which is in line with the reported prevalence in
healthy control populations of Caucasians21 and with the
prevalence in a larger German cohort of patients with MS.22
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Ethnicity of our cohort was homogeneous. Of note, 94.6% of
the patients had grandparents of German origin only. The
others (5.4%) had 1 grandparent with origin other than
German. There were no patients with more than 1 grand-
parent with origin other than German enrolled in this study.
After preselection as described above, the parameters Ex-
panded Disability Status Scale (EDSS) score, BMI, BDI-II,
FSMC, alcohol consumption, smoking, MRI lesion number,
and APOE e4 carrier status were included in a multiple linear
regression model for the prediction of the overall cognitive
performance evaluated by the mean score of the
z-standardized PASAT 3 andMUSIC test scores. It was found
that APOE e4 homozygosity, higher disability level measured
by the EDSS, higher MRI lesion number, and higher BDI-II
scores were associated with lower performance in cognitive
testing, whereas patients who consumed alcohol scored
higher compared with patients who did not consume alcohol
Table 1 Patient characteristics
Number (%) Median (IQR)
Demographic characteristics
Sex
Female 395 (71.6)
Male 157 (28.4)
Age (y) 32 (27–42)
Education (school leaving
level)
Level 1 60 (10.9)
Level 2 251 (45.5)
Level 3 241 (43.7)
Ethnic origin of grandparents
Only German 522 (94.6)
One other than German 30 (5.4)
Clinical characteristics
Diagnosis
CIS 244 (44.2)
RRMS 308 (55.8)
Disease duration (mo) 4 (2–9)
EDSS score 1.5 (1.0–2.0)
Occurrence of relapse within
30 days
Relapse 76 (13.8)
No relapse 468 (84.8)
No information 8 (1.4)
BMI 24.1 (21.6–27.7)
BDI-II 5.0 (2.0–9.0)
Fatigue score (FSMC) 15.00
(11.00–25.75)
Current smoking
Smokers 172 (31.2)
Nonsmokers 380 (68.8)
Alcohol consumption
Occasional or regular
drinking
426 (77.2)
No drinking 126 (22.8)
MRI characteristics
Lesion number 9 (6–9)
Lesion localization
Periventricular (yes/no) 528 (95.7)/24 (4.3)
Juxtacortical (yes/no) 416 (75.4)/136
(24.6)
Table 1 Patient characteristics (continued)
Number (%) Median (IQR)
Infratentorial (yes/no) 319 (57.8)/233
(42.2)
Presence of CEL
Yes 197 8 (35.7)
No 340 (61.6)
No information 15 (2.7)
Black holes
Yes 243 (44.0)
No 172 (31.2)
No information 137 (24.8)
Visible atrophy
Yes 46 (8.3)
No 396 (71.7)
No information 110 (19.9)
Genetic characteristics
APOE «4 carriers
Homozygotes e4/e4 10 (1.8)
Heterozygotes e4/e3 or e4/e2 129 (23.4)
APOE «4 noncarriers e3/e3 or e2/e3 or
e2/e2
413 (74.8)
Abbreviations: BDI-II = Beck Depression Inventory II; BMI = bodymass index;
CEL = contrast-enhancing lesion; CIS = clinically isolated syndrome; EDSS =
Expanded Disability Status Scale; FSMC = Fatigue Scale for Motor and Cog-
nitive Function; IQR: interquartile range; RRMS = relapsing-remitting MS.
The table summarizes the assumed predictors of cognitive performance
and their baseline characteristics in our cohort of 552 patients with CIS and
early RRMS. Age and education were used for the z-standardization and
were therefore not included in the regressionmodels. Continuous variables
are described by their median and interquartile range, and categorical
variables by numbers and percentages.
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(table 2). The R2 of the overall model was 0.133 (adjusted R2
= 0.118). APOE e4 heterozygosity was not associated with the
overall cognitive performance.
To evaluate whether the effect of APOE e4 carrier status was
more pronounced in memory-mediated cognitive domains
resembling its effects in AD, a sum score of the memory-
centered subparts of the MUSIC test was investigated in
a second multiple linear regression model. However, we found
no relevant association of APOE e4 homo- or heterozygosity
with the memory-centered sum score in the univariate re-
gression analysis. Therefore, APOE e4 carrier status was not
included in the multiple regression model for the memory-
centered sum score. We found that male sex and higher EDSS
scores were associated with worse performance in these subt-
ests. In line with the results of the mean score of overall cog-
nitive performance, alcohol consumption was associated with
better test results again (table 3). The R2 of the overall model
was 0.109 (adjusted R2 = 0.094).
The findings concerning the effect of alcohol consumption are
limited by the fact that they were no longer detectable after
variation of dichotomization into nondrinkers and occassional
drinkers vs regular drinkers.
We observed no association of theAPOE e2 carrier status with
any of the cognitive outcome parameters in the univariate
regression analyses. Therefore, APOE e2 carrier status was not
included in any of the multiple linear regression models.
Discussion
Cognitive impairment is one of the most difficult challenges
for young adults faced with a diagnosis of MS because neu-
ropsychological symptoms may already be experienced early
on23,24 and are among the main reasons for unemployment
and reduced quality of life.25 We here assessed the putative
role of APOE polymorphisms on the cognitive outcome
parameters PASAT 3 and MUSIC test scores in patients with
CIS and early RRMS of a homogenous cohort in terms of
origin, short disease duration, and treatment-naive state.
Neither APOE e2 carrier status nor APOE e4 heterozygosity
showed an influence on the evaluated cognitive outcome
parameters. However, we observed a relevant association of
APOE e4 homozygosity with a lower overall cognitive
performance.
In AD, APOE e4 carriers have a higher risk of developing AD
and show decreased APOE plasma levels compared with
APOE e2 and APOE e3 carriers. Among APOE e4 carriers,
lower plasma levels are associated with an even greater risk of
developing AD. Therefore, it was suggested that a decrease of
Table 2 Regression coefficients for mean cognitive test scores
CI
β SE Standardized β t Value 95% lower 95% upper p Value
Intercept 0.920 0.341 2.698 0.250 1.590 0.007
Genetic characteristics
APOE «4 homozygosity 20.922 0.394 20.095 22.340 21.697 20.148 0.020
APOE «4 heterozygosity 0.128 0.124 0.043 1.035 −0.115 0.372 0.301
Clinical characteristics
Disability (EDSS score) 20.180 0.057 20.135 23.143 20.293 20.068 0.002
BMI −0.010 0.010 −0.041 −0.987 −0.031 0.010 0.324
Depressive symptoms (BDI-II) 20.021 0.010 20.116 22.024 20.040 20.001 0.043
Fatigue score (FSMC) −0.005 0.004 −0.065 −1.121 −0.013 0.003 0.263
Alcohol consumption 0.493 0.126 0.160 3.929 0.247 0.740 <0.001
Smoking −0.221 0.115 −0.079 −1.932 −0.446 0.004 0.054
MRI characteristics
Lesion number 20.056 0.022 20.103 22.514 20.099 20.012 0.012
Abbreviations: β = regression coefficient; BDI-II = Beck Depression Inventory II; BMI = body mass index; EDSS = Expanded Disability Status Scale; FSMC =
Fatigue Scale for Motor and Cognitive Function; MUSIC = Multiple Sclerosis Inventory Cognition; SE = standard error.
As a proxy for overall cognitive performance, themean of the z-standardized PASAT 3 andMUSIC total scores was calculated. The following parameters were
selected for inclusion in the multiple linear regression model: EDSS score, BMI, BDI-II FSMC, alcohol consumption, smoking, MRI lesion number, and APOE e4
carrier status (n = 545). APOE e4 homozygosity, higher disability level measured by the EDSS, higher MRI lesion number, and higher BDI-II scores were
associatedwith lower performance in cognitive testing, whereas patientswho consumedalcohol scored higher comparedwith patientswho did not consume
alcohol. Parameters, which were found to be relevant predictors (defined by p < 0.05) of mean cognitive test scores, are written in bold.
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APOE protein functionmediates the evolution of AD and that
the risk increases dose dependently.3 As APOE is thought to
be involved in repairing neuronal injury, synapse formation,
and scavenging of toxins,26,27 we hypothesized that impaired
repair mechanisms in MS lesions could mediate more pro-
nounced neurodegenerative processes in APOE e4 carriers
compared with noncarriers.
Our current finding that cognitive performance was impaired
in homozygous APOE e4 carriers only might indicate that
a dose-dependent decrease of APOE function mediates cog-
nitive decline in MS, as it does in AD, and that a prolonged
follow-up would reveal more pronounced effects of APOE
later in the course of MS. Supporting this, previous studies in
smaller cohorts of patients with MS with mean disease
durations of 8.328 and 13 years26 reported an association of
APOE e4 with dysfunction in some cognitive domains in-
cluding verbal fluency and memory.
To evaluate whether the observed negative impact of APOE
e4 homozygosity on cognitive performance was mainly
caused by impaired memory functions, resembling the as-
sumed APOE e4-mediated effects in AD,29 additional analysis
of a memory-centered sum score was performed. However,
we found no relevant association of APOE e4 homo- or het-
erozygosity with this memory-centered sum score. This might
indicate an AD-independent APOE e4-mediated effect on
cognitive performance in patients with MS. This hypothesis is
also supported by the young median age of our cohort as
APOE e4-dependent progression of formerly cognitive un-
impaired people to mild cognitive impairment (MCI) and AD
was found to be most pronounced in older people aged 70–75
years.30 Furthermore, a recent study using PET imaging
biomarkers of AD even suggested that some aspects of MS
pathobiology retard the accumulation of β-amyloid, which is
one of the main pathologic correlates of AD.31 Nevertheless,
we cannot exclude the possibility that patients with APOE e4
homozygosity performed worse in the cognitive tests because
of an APOE e4-mediated increased risk of developing MCI
or AD.
In an effort to correct for potential confounders, we included
a range of parameters known or assumed to influence cog-
nitive performance in patients with MS in our analyses. Apart
from the putative impact of APOE e4 homozygosity, we ob-
served a relevant association of markers of the disease burden
with the overall cognitive performance. Patients with a higher
disability level as assessed by the EDSS and with a higher
number of T2 lesions in MRI performed worse in cognitive
testing, which is in line with previous reports.17,23,32 Higher
scores of depressive symptoms in BDI-II were also associated
with an impaired performance. Depression is known to be
Table 3 Regression coefficients of the memory-centered MUSIC test subparts
CI
Β SE Standardized β t Value 95% lower 95% upper p Value
Intercept 0.443 0.301 1.469 −0.149 1.035 0.142
Demographic characteristics
Sex (female vs male) 0.370 0.088 0.176 4.178 0.196 0.543 <0.001
Clinical characteristics
Disease duration (mo) −0.006 0.005 −0.052 −1.249 −0.016 0.004 0.212
Disability (EDSS score) 20.123 0.043 20.127 22.882 20.206 20.039 0.004
BMI −0.014 0.008 −0.079 −1.867 −0.029 0.001 0.062
Depressive symptoms (BDI-II) −0.008 0.007 −0.064 −1.108 −0.023 0.006 0.268
Fatigue score (FSMC) −0.002 0.003 −0.046 −0.775 −0.008 0.004 0.439
Alcohol consumption 0.236 0.093 0.106 2.536 0.053 0.418 0.012
Smoking −0.156 0.085 −0.077 −1.842 −0.322 0.010 0.066
MRI characteristics
Lesion number −0.025 0.016 −0.064 −1.536 −0.057 0.007 0.125
Abbreviations: BDI-II = Beck Depression Inventory II; BMI = body mass index; EDSS = Expanded Disability Status Scale; FSMC = Fatigue Scale for Motor and
Cognitive Function; SE = standard error.
A sum score of thememory-centered subparts of theMUSIC test (Wordlist A and B and verbal recall) was calculated to evaluate the potential effect of APOE e4
carrier status on memory function. However, APOE e4 carrier status did not show any association with this sum score in the preselection process and was
therefore not included in the regression model. The following parameters were selected for inclusion in the multiple linear regression model: sex, disease
duration, EDSS score, BMI, BDI-II, FSMC, alcohol consumption, smoking, and MRI lesion number (n = 538). Female sex, lower disability level measured by the
EDSS, and alcohol consumption were associated with better performance in the memory-centered subtests of MUSIC. Parameters, which were found to be
relevant predictors (defined by p < 0.05) of mean cognitive test scores, are written in bold.
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associated with reduced attention and processing speed in
patients with MS.33 As PASAT 3 and MUSIC tests both in-
clude an assessment of these cognitive domains, our current
finding seems plausible. Surprisingly, we observed a positive
influence of alcohol consumption on the cognitive outcome,
shedding light on recent reports associating alcohol con-
sumption with lower neurologic disability in MS,34 and a re-
duced risk of developing MS.35 However, this finding has to
be interpreted with care as it may be attributed to the di-
chotomization of drinking habits and as the questionnaires
used in this study were not laid out for accurate quantification
of alcohol consumption (e.g., units/month).
Two additional limitations of this study have to be addressed.
First, the observed effect of APOE e4 is based on a very low
number of APOE e4 homozygotes, which makes our findings
sensitive to potential confounders, not accounted for. As the
estimated prevalence of APOE e4 homozygosity in Caucasian
MS populations is only 1.8%, an even larger cohort than ours
would be needed to improve the statistical power. Second, the
tests used to assess cognitive performance in this study pose
another potential limitation of our observations. PASAT 3
and MUSIC are both screening tests for cognitive perfor-
mance, which offer the advantage that they may be in-
corporated into routine diagnostics comparatively easily.
However, they lack the sensitivity and reliability to detect MS-
specific cognitive impairment of extended test batteries, like
for instance the Symbol Digit Modalities Test.36
Besides markers of disease burden, depression, and lifestyle
habits, this study identified APOE e4 homozygosity as a po-
tential predictor of cognitive performance in this cohort of
patients with CIS and early RRMS. This indicates a role of
APOE as a genetic risk factor for cognitive impairment in MS
and might even suggest an APOE e4 effect unrelated to
concomitant AD. Therefore, future work confirming the
current findings in young homozygous APOE e4 patients in
a larger and independent MS cohort would be valuable.
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